Postpartum antiretroviral drug resistance in HIV-1-infected women receiving pregnancy-limited antiretroviral therapy

AIDS

Volumn 24, Issue 1, 2010, Pages 45-53

  Paredes, Roger ^a,b   Cheng, Irene ^c   Kuritzkes, Daniel R ^a   Tuomala, Ruth E ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c Clinical Trials & Surveys Corp   (United States)

Author keywords

Allele specific PCR; HIV 1; Minor variants; Mother to child transmission; Pregnancy; Resistance

Indexed keywords

EFAVIRENZ; EMTRICITABINE; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA; ZIDOVUDINE;

ADULT; ARTICLE; FEMALE; GENE MUTATION; GENE SEQUENCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MUTATION RATE; NONHUMAN; POLYMERASE CHAIN REACTION; PREGNANT WOMAN; PRIORITY JOURNAL; PUERPERIUM; VIRUS RESISTANCE;

ADULT; ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; INFANT, NEWBORN; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; LAMIVUDINE; MUTATION; NELFINAVIR; NEVIRAPINE; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; ZIDOVUDINE;

EID: 73649091095     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32832e5303     Document Type: Article

References (41)

1. Townsend CL, Cortina-Borja M, Peckham CS, de Ruiter A, Lyall H, Tookey PA. Low rates of mother-to-child transmission of HIV following effective pregnancy interventions in the United Kingdom and Ireland, 2000-2006. AIDS 2008; 22:973-981.
2. Horvath T, Madi BC, Iuppa IM, Kennedy GE, Rutherford G, Read JS. Interventions for preventing late postnatal mother-to-child transmission of HIV. Cochrane Database Syst Rev 2009: CD006734.
3. Suksomboon N, Poolsup N, Ket-Aim S. Systematic review of the efficacy of antiretroviral therapies for reducing the risk of mother-to-child transmission of HIV infection. J Clin Pharm Ther 2007; 32:293-311.
4. Volmink J, Siegfried NL, van der Merwe L, Brocklehurst P. Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection. Cochrane Database Syst Rev 2007: CD003510.
5. Read JS, Newell MK. Efficacy and safety of cesarean delivery for prevention of mother-to-child transmission of HIV-1. Cochrane Database Syst Rev 2005:CD005479.
6. Guay LA, Musoke P, Fleming T, Bagenda D, Allen M, Nakabiito C, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet 1999; 354:795-802.
7. Arrive E, Newell ML, Ekouevi DK, Chaix ML, Thiebaut R, Masquelier B, et al. Prevalence of resistance to nevirapine in mothers and children after single-dose exposure to prevent vertical transmission of HIV-1: a meta-analysis. Int J Epidemiol 2007; 36:1009-1021.
8. Paredes R, Cheng I, Kuritzkes DR, Tuomala RE. High prevalence of primary lamivudine and nelfinavir resistance in HIV-1-in-fected pregnant women in the United States, 1998-2004. AIDS 2007; 21:2103-2106.
9. Shah SS, Crane M, Monaghan K, McGowan JP. Genotypic resistance testing in HIV-infected pregnant women in an urban setting. Int J STD AIDS 2004; 15:384-387.
10. Henry M, Thuret I, Solas C, Genot S, Colson P, Tamalet C. Vertical transmission of multidrug-resistant Q151M human immunodeficiency virus type 1 strains. Pediatr Infect Dis J 2008; 27:278-280.
11. Martinson NA, Morris L, Gray G, Moodley D, Pillay V, Cohen S, et al. Selection and persistence of viral resistance in HIV-infected children after exposure to single-dose nevirapine. J Acquir Immune Defic Syndr 2007; 44:148-153.
12. Lee EJ, Kantor R, Zijenah L, Sheldon W, Emel L, Mateta P, et al. Breast-milk shedding of drug-resistant HIV-1 subtype C in women exposed to single-dose nevirapine. J Infect Dis 2005; 192:1260-1264.
13. Johnson VA, Petropoulos CJ, Woods CR, Hazelwood JD, Parkin NT, Hamilton CD, Fiscus SA. Vertical transmission of multi-drug-resistant human immunodeficiency virus type 1 (HIV-1) and continued evolution of drug resistance in an HIV-1-infected infant. J Infect Dis 2001; 183:1688-1693.
14. Eshleman SH, MracnaM, Guay LA, DeseyveM, Cunningham S, Mirochnick M, et al. Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012). AIDS 2001; 15:1951-1957.
15. Siegrist CA, Yerly S, Kaiser L, Wyler CA, Perrin L. Mother to child transmission of zidovudine-resistant HIV-1. Lancet 1994; 344:1771-1772.
16. Jourdain G, Ngo-Giang-Huong N, Le Coeur S, Bowonwatanu-wong C, Kantipong P, Leechanachai P, et al. Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy. N Engl J Med 2004; 351:229-240.
17. Paredes R, Lalama C, Ribaudo H, Schackman B, Shikuma C, Meyer W, et al. Presence of minor populations of Y181C mutants detected by Allele-Specific PCR (ASPCR) and risk of efavirenz failure in treatment-näive patients: results of an ACTG 5095 case-cohort study. In: 15th Conference on Retro-viruses and Opportunistic Infections; Boston; 2008.
18. Coffie PA, Ekouevi DK, Chaix ML, Tonwe-Gold B, Clarisse AB, Becquet R, et al. Maternal 12-month response to antiretroviral therapy following prevention of mother-to-child transmission of HIV type 1, Ivory Coast, 2003-2006. Clin Infect Dis 2008; 46:611-621.
19. Lockman S, Shapiro RL, Smeaton LM, Wester C, Thior I, Stevens L, et al. Responsetoantiretroviraltherapy afterasingle, peripartum dose of nevirapine. N Engl J Med 2007; 356:135-147.
20. Sheon AR, Fox HE, Rich KC, Stratton P, Diaz C, Tuomala R, et al. The women and infants transmission study (WITS) of maternal-infant HIV transmission: study design, methods and baseline data. J Womens Health 1996; 5:69-78.
21. Johnson VA, Brun-Vezinet F, Clotet B, Gunthard HF, Kuritzkes DR, Pillay D, et al. Update of the drug resistance mutations in HIV-1: Spring 2008. Top HIV Med 2008; 16:62-68.
22. Paredes R, Marconi VC, Campbell TB, Kuritzkes DR. Systematic evaluation of allele-specific real-time PCR for the detection of minor HIV-1 variants with pol and env resistance mutations. J Virol Methods 2007; 146:136-146.
23. Lin HJ, Tanwandee T, Hollinger FB. Improved methods for quantification of human immunodeficiency virus type 1 RNA and hepatitis C virus RNA in blood using spin column technology and chemiluminescent assays of PCR products. J Med Virol 1997; 51:56-63.
24. Paredes R, Marconi VC, Campbell TB, Kuritzkes DR. Systematic evaluation of allele-specific real-time PCR for the detection of minor HIV-1 variants with pol and env resistance mutations. J Virol Methods 2007; 146:136-146.
25. 0- thiacytidine in patients with AIDS or advanced AIDS-related complex. AIDS 1995; 9:351-357.
26. 0-thiacyti-dine. Antimicrob Agents Chemother 1993; 37:1390-1392.
27. Duran AS, Losso MH, Salomon H, Harris DR, Pampuro S, Soto-Ramirez LE, et al. Drug resistance among HIV-infected pregnant women receiving antiretrovirals for prophylaxis. AIDS 2007; 21:199-205.
28. Welles SL, Bauer GR, LaRussa PS, Colgrove RC, Pitt J. Time trends for HIV-1 antiretroviral resistance among antiretroviral-experienced and naive pregnant women in New York City during 1991 to early 2001. J Acquir Immune Defic Syndr 2007; 44:329-335.
29. Cohn SE, Umbleja T, Mrus J, Bardeguez AD, Andersen JW, Chesney MA. Prior illicit drug use and missed prenatal vitamins predict nonadherence to antiretroviral therapy in pregnancy: adherence analysis A5084. AIDS Patient Care STDS 2008; 22:29-40.
30. Mellins CA, Chu C, Malee K, Allison S, Smith R, Harris L, et al. Adherence to antiretroviral treatment among pregnant and postpartum HIV-infected women. AIDS Care 2008; 20:958-968.
31. Schackman BR, Ribaudo HJ, Krambrink A, Hughes V, Kuritzkes DR, Gulick RM. Racial differences in virologic failure associated with adherence and quality of life on efavirenz-contain-ing regimens for initial HIV therapy: results of ACTG A5095. J Acquir Immune Defic Syndr 2007; 46:547-554.
32. Bryson YJ, Mirochnick M, Stek A, Mofenson LM, Connor J, Capparelli E, et al. Pharmacokinetics and safety of nelfinavir when used in combination with zidovudine and lamivudine in HIV-infected pregnant women: Pediatric AIDS Clinical Trials Group (PACTG) Protocol 353. HIV Clin Trials 2008; 9:115-125.
33. Unadkat JD, Wara DW, Hughes MD, Mathias AA, Holland DT, Paul ME, et al. Pharmacokinetics and safety of indinavir in human immunodeficiency virus-infected pregnant women. Antimicrob Agents Chemother 2007; 51:783-786.
34. Nellen JF, Schillevoort I, Wit FW, Bergshoeff AS, Godfried MH, Boer K, et al. Nelfinavir plasma concentrations are low during pregnancy. Clin Infect Dis 2004; 39:736-740.
35. Mathias AA, Maggio-Price L, Lai Y, Gupta A, Unadkat JD. Changes in pharmacokinetics of anti-HIV protease inhibitors during pregnancy: the role of CYP3A and P-glycoprotein. J Pharmacol Exp Ther 2006; 316:1202-1209.
36. Stek AM, Mirochnick M, Capparelli E, Best BM, Hu C, Burchett SK, et al. Reduced lopinavir exposure during pregnancy. AIDS 2006; 20:1931-1939.
37. von Hentig N, Carlebach A, Gute P, Knecht G, Klauke S, Rohrbacher M, et al. A comparison of the steady-state phar-macokinetics of nevirapine in men, nonpregnant women and women in late pregnancy. Br J Clin Pharmacol 2006; 62:552-559.
38. Chaix ML, Ekouevi DK, Peytavin G, Rouet F, Tonwe-Gold B, Viho I, et al. Impact of nevirapine (NVP) plasma concentration on selection of resistant virus in mothers who received single-dose NVP to prevent perinatal human immunodeficiency virus type 1 transmission and persistence of resistant virus in their infected children. Antimicrob Agents Chemother 2007; 51:896-901.
39. Metzner KJ, Rauch P, Walter H, Boesecke C, Zollner B, Jessen H, et al. Detection of minor populations of drug-resistant HIV-1 in acute seroconverters. AIDS 2005; 19:1819-1825.
40. Simen BB, Huppler Hullsiek K, Novak RM, MacArthur RD, Baxter JD, Huang C, et al. Prevalence of Low abundance drug resistant variants by ultra-deep sequencing in chronically HIV-infected antiretroviral (ARV) naive patients and the impact on virologic outcomes. In: 16th International HIV Drug Resistance Workshop; Barbados, West Indies; June 12-16, 2007. 2007.
41. Perinatal HIV Guidelines Working Group. Public Health Service Task Force recommendations for use of antiretroviral drugs in pregnant HIV-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. November 2, 2007. 1-96. http://aidsinfo.nih.gov/ContentFiles/ PerinatalGL.pdf. [Accessed: July 28th, 2008]